Everolimus in Patients (pts) with Advanced Lung Carcinoids: Evaluation of Median Progression Free Survival (PFS) and Median Time to First Dose Decrease or Discontinuation (DDD) Abstract #1225

Introduction: Treatment of well-differentiated (WD) lung neuroendocrine tumors (NETs) is challenging. Everolimus (mTOR inhibitor) has shown encouraging results in digestive NETs but data about its activity on lung carcinoid are sparse.
Aim(s): The aim of our study was to assess antitumoral efficacy and tolerability of everolimus in lung NETs.
Materials and methods: Consecutive pts with progressive advanced WD lung NETs treated with everolimus at Gustave Roussy between Sep 2007 and Feb 2014 were analyzed. Treatment regimen with oral everolimus was 10 mg daily. Primary end-points were median PFS and median time to first DDD. Secondary objective were overall survival (OS), best response (RECIST v1.1) and safety.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Letizia Gianoncelli

To read results and conclusion, please login ...

Further abstracts you may be interested in

#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors
Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Iida S, Miki Y, Ono K, Sasano H
#220 The Global mTOR Inhibitor Torin1 is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylases Inhibitors, in Suppressing Neuroendocrine Tumors Cell Proliferation
Introduction: Torin1, a new mTOR inhibitor that globally inhibits both mTORC1 and mTORC2, seems to impair cell growth and proliferation to a greater degree than rapamycin; its effects in NET cells are unknown.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr. Simona Grozinsky-Glasberg
#320 Predictors of Clinical Response to Everolimus in Patients with Well-differentiated Metastatic Pancreatic NETs
Introduction: Everolimus (E) is an mTOR inhibitor with promising antitumor activity in patients with NETs. Predictor factors of response could improve the clinical use of this compound.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Cristina De Martino
#334 Everolimus + Octreotide LAR v. Placebo + Octreotide LAR in Patients With Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)
Introduction: Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase 2 studies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Marianne Pavel
#392 A 67-Year Old Woman with a Carcinoid Tumor of the Coccyx with Liver Metastases
Introduction: Neuroendocrine tumors (NETs) are tumors of the interface between the endocrine and nervous system. They are characterized by the presence of secretory granules, as well as the ability to produce biogenic amines and polypeptide hormones. The clinical behavior of NETs is extremely variable; they may be functioning or non-functioning, ranging from very slow-growing tumors, which are the majority, to highly aggressive and very malignant tumors. Many case reports of rare sites of primary NETs outside the gastrointestinal tract have been described, as tumors with neuroendocrine characteristics can occur in virtually any organ or tissue. Nevertheless, this is the first case of a metastatic coccygeal carcinoid tumor ever described.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Theodors Angelopoulos